close
References
  1. American College of Rheumatology. Rheumatoid arthritis: Fast facts. What is rheumatoid arthritis? Last updated March 2019. www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Rheumatoid-Arthritis. Accessed November 27, 2020.
  2. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1-26.
  3. Banerjee S, Compton AP, Hooker RS, et al. Cardiovascular outcomes in male veterans with rheumatoid arthritis. Am J Cardiol. 2008;101(8):1201-1205.
  4. Cannon GW. Optimizing rheumatoid arthritis disease modifying anti-rheumatic drugs. Health Services Research and Development Study SHP 08-172 2008. www.hsrd.research.va.gov/research/abstracts.cfm?Project_ID=2141698764. Accessed November 29, 2020.
  5. Mikuls TR, Reimold A, Kerr GS, Cannon GW. Insights and implications of the VA Rheumatoid Arthritis Registry. Fed Pract. 2015;32(5):24-29.
  6. Burbach K. Registry spurs research participation by veterans. UNMC Newsroom. November 3, 2017. www.unmc.edu/news.cfm?match=21214. Accessed November 27, 2020.
  7. Mikuls TR, Fay BT, Michaud K, et al. Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford). 2011;50(1):101-109.
  8. Walsh JA, Pei S, Penmetsa GK, et al. Treatment patterns with disease-modifying antirheumatic drugs in U.S. veterans with newly diagnosed rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. J Manag Care Spec Pharm. 2019;25(11):1218-1228.
  9. El Jammal T, Sève P, Gerfaud-Valentin M, Jamilloux Y. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis. Expert Opin Pharmacother. 2020;23:1-14.
  10. O'Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(suppl 2):ii111-ii115.
  11. Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(suppl 1):i17-i26.
  12. Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol. 2016;32:29-33.
  13. Fraenkel L. ACR 2020 Pharmacologic treatment recommendations for RA. Presented at: American College of Rheumatology (ACR) Convergence virtual meeting; November 9, 2020.
  14. American College of Rheumatology. New rheumatoid arthritis guideline emphasizes maximizing methotrexate and biologics, minimizing steroids. Newswise. November 6, 2020. www.newswise.com/articles/new-rheumatoid-arthritis-guideline-emphasizes-maximizing-methotrexate-and-biologics-minimizing-steroids. Accessed November 27, 2020.
  15. Volansky R. Emerging therapies, novel approaches in RA change the ‘default’. November 19, 2020. Healio Rheumatology News. www.healio.com/news/rheumatology/20201119/emerging-therapies-novel-approaches-in-ra-change-the-default. Accessed November 27, 2020.
  16. Rao M. ACR 2020 Debate: JAK inhibitors vs biologics after methotrexate failure in RA. November 12, 2020. Rheumatology Advisor. www.rheumatologyadvisor.com/home/conference-highlights/acr-convergence-2020/debate-american-college-rheumatology-2020-jak-inhibitors-vs-biologics-in-rheumatoid-arthritis/. Accessed November 27, 2020.
  17. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652-662.
  18. Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788-1800.
  19. Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383(16):1511-1521.
  20. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;6:15.
  21. Fleischmann R, Kremer J, Cush J, et al; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495-507.
  22. van Vollenhoven RF, Fleischmann R, Cohen S, et al; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508-519.
  23. Burmester GR, Blanco R, Charles-Schoeman C, et al; ORAL Step Investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451-460.
  24. Strand V, Kremer JM, Gruben D, Krishnaswami S, Zwillich SH, Wallenstein GV. Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient-reported outcomes from a phase III randomized controlled trial. Arthritis Care Res (Hoboken). 2017;69(4):592-598.
  25. Lee EB, Fleischmann R, Hall S, et al; ORAL Start Investigators. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370(25):2377-2386.
  26. van der Heijde D, Strand V, Tanaka Y, et al; ORAL Scan Investigators. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four month, phase III study. Arthritis Rheumatol. 2019;71(6):878-891.
  27. Fleischmann R, Mysler E, Hall S, et al; ORAL Strategy Investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457-468.
  28. Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89.
  29. Olumiant [prescribing information]. Eli Lilly and Company. 2020.
  30. Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506-517.
  31. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88-95.
  32. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243-1252.
  33. Smolen JS, Kremer JM, Gaich CL, et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis. 2017;76(4):694-700.
  34. van der Heijde D, Kartman CE, Xie L, et al. Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: results from RA-BEYOND [abstract 1235]. American College of Rheumatology, ACR Convergence virtual meeting, November 5-9, 2020. https://acrabstracts.org/abstract/radiographic-progression-of-structural-joint-damage-over-5-years-of-baricitinib-treatment-in-patients-with-rheumatoid-arthritis-results-from-ra-beyond/. Accessed November 29, 2020.
  35. Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519-531.
  36. Rinvoq [prescribing information]. Abbvie, Inc. 2020.
  37. Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30(5):779-787.
  38. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503-2512.
  39. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513-2524.
  40. van Vollenhoven R, Takeuchi T, Pangan AL, et al. A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis [abstract 891]. Arthritis Rheumatol. 2018;70(suppl 10):abstract 891.
  41. Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303-2311.
  42. Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019;78(11):1454-1462.
  43. Choy EH. Clinical significance of Janus Kinase inhibitor selectivity [published correction appears in Rheumatology (Oxford). 2019;58(6):1122]. Rheumatology (Oxford). 2019;58(6):953-962.
  44. Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.
  45. Lee YH, Song GG. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs. Z Rheumatol. 2020. [Epub ahead of print].
  46. Fautrel B, Zhu B, Taylor PC, et al. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison. RMD Open. 2020;6(1):e001131.
  47. Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(suppl 1):i34-i42.
  48. Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 5.5 years: an updated integrated safety analysis [abstract 511]. Arthritis Rheumatol. 2017;69(suppl 10):abstract 511.
  49. Fleischmann R, Wollenhaupt J, Takiya L, et al. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open. 2017;3(2):e000491.
  50. Harigai M, Honda S. Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: is expectation the root of all headaches? Drugs. 2020;80(12):1183-1201.
  51. Xeljanz [prescribing information]. Pfizer, Inc. 2020.
  52. Kremer J, Huizinga TWJ, Chen L, et al. Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis [abstract FRI0090]. Ann Rheum Dis. 2017;76(suppl 2):512.
  53. Yates M, Mootoo A, Adas M, et al. Venous thromboembolism risk with JAK inhibitors: a meta-analysis. Arthritis Rheumatol. 2020. [Epub ahead of print].
  54. Xie W, Zhang Z. Tofacitinib in cardiovascular outcomes: friend or foe? Rheumatology (Oxford). 2020;59(8):1797-1798.
  55. Charles-Schoeman C, DeMasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71(9):1450-1459.
  56. Xie W, Xiao S, Huang Y, Sun X, Zhang Z. Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. 2019;11:1-18.
  57. Kremer J, Bingham C, Cappelli L, et al. Post-approval comparative safety study of tofacitinib and biologic DMARDs: five-year results from a US-based rheumatoid arthritis registry [abstract OP0028]. Ann Rheum Dis. 2019;78(suppl 2):82-83.
  58. Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, long-term extension studies. J Rheumatol. 2014;41(5):837-852.
  59. Kay J, Harigai M, Rancourt J, et al. Effects of baricitinib on haemoglobin and related laboratory parameters in rheumatoid arthritis patients. Ann Rheum Dis. 2017;76(suppl 2):513-514.
  60. Xie F, Yun H, Bernatsky S, Curtis JR. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68(11):2612-2617.
  61. Combe B, Kivitz A, Tanaka Y, et al. Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results [abstract LB0001]. Ann Rheum Dis. 2019;78(suppl 2):77-78.
  62. Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy. The FINCH 2 Randomized Clinical Trial. JAMA. 2019;322(4):315-325.
  63. Clinicaltrials.gov. A randomized, double-blind, placebo- and active-controlled, multicenter, phase 3 study to assess the efficacy and safety of filgotinib administered for 52 weeks alone and in combination with methotrexate (MTX) to subjects with moderately to severely active rheumatoid arthritis who are naïve to MTX therapy (FINCH 3). www.clinicaltrials.gov/ct2/show/NCT02886728?term=finch3&draw=2&rank=1. Accessed November 30, 2020.
  64. Clinicaltrials.gov. Long-term extension study to assess the safety and efficacy of filgotinib in adults with rheumatoid arthritis (FINCH 4). www.clinicaltrials.gov/ct2/show/NCT03025308?term=finch4&draw=2&rank=1. Accessed November 30, 2020.
  65. Taylor NP. FDA rejects Gilead's would-be blockbuster filgotinib over toxicity concerns. August 19, 2020. FierceBiotech. www.fiercebiotech.com/biotech/fda-rejects-gilead-s-would-be-blockbuster-filgotinib-over-toxicity-concerns. Accessed November 29, 2020.
  66. Tanaka Y, Izutsu H. Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. Expert Opin Pharmacother. 2020;21(9):1015-1025.
  67. Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019;78(10):1320-1332.
  68. Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019;78(10):1305-1319.
  69. Takeuchi T, Tanaka Y, Iwasaki M, Ishikura H, Saeki S, Kaneko Y. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75(6):1057-1064.